Abstract:Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors are the first and most successful drugs designed to exploit the concept of synthetic lethality (SL) between PARP-1 and BRCA1/2, which provides a novel strategy for tumor treatment. However, narrowed indications and resistance to PARP-1 inhibitors have hampered their further clinical application. Inducing "BRCAness" by targeting other targets, which will directly or indirectly disturb the homologous recombination (HR) repair pathway of double-strand DNA breaks (DSBs), is a promising strategy for expanding the clinical application of PARP-1 inhibitors and overcoming resistance to these inhibitors. Tankyrase1/2 (TNKS1/2) are involved in the nonhomologous end-joining (NHEJ) DNA repair pathway by regulating Wnt/β-catenin signaling. TNKS1/2 can also induce a "BRCAness" phenotype by regulating Wnt signaling, which increases the sensitivity of tumor cells with BRCA proficiency to PARP-1 inhibitors. These results suggest that cotargeting PARP1/2 and TNKS1/2 not only exerts a synergistic effect in the treatment of tumors but also provides a novel strategy for expanding the clinical application of PARP-1 inhibitors and overcoming resistance to PARP-1 inhibitors. Therefore, a series of dual PARP-1/2 and TNKS1/2 inhibitors were rationally designed, synthesized, and evaluated for their pharmacological properties. Among these candidates, compound I-9 showed excellent inhibitory activity as it inhibited PARP-1/2 and TNKS1/2 with IC50 values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM, respectively. I-9 exhibited favorable synergistic antitumor efficacy in both BRCA-mutant and BRCA-wild-type cancer lines. Moreover, I-9 exerted prominent dose-dependent antitumor activity in an HCT116 cell-derived xenograft model and was significantly more efficacious than olaparib and E7449. Overall, the present study indicated that I-9, a dual PARP-1/2 and TNKS1/2 inhibitor, is a novel and promising agent for cancer therapy.

Design, Synthesis, and Biological Evaluation of Novel 4,4′-Bipyridine Derivatives Acting As CDK9-Cyclin T1 Protein-Protein Interaction Inhibitors Against Triple-Negative Breast Cancer

Inhibition of the CDK9–cyclin T1 protein–protein interaction as a new approach against triple-negative breast cancer

Discovery of a Tetrahydroisoquinoline-Based CDK9-cyclin T1 Protein–protein Interaction Inhibitor As an Anti-Proliferative and Anti-Migration Agent Against Triple-Negative Breast Cancer Cells

Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer

Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA

Discovery and identification of a novel PI3K inhibitor with enhanced CDK2 inhibition for the treatment of triple negative breast cancer

Design, Synthesis and Anticancer Evaluation of Selective 2,4-Disubstituted Pyrimidine CDK9 Inhibitors

Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer

Discovery of Novel PI3K/CDK2 Dual Inhibitor Based on 7-Azaindole Derivatives As a Promising Strategy for Triple-Negative Breast Cancer Therapy

Identification and evaluation of a novel PARP1 inhibitor for the treatment of triple-negative breast cancer

Structure-Based Design of 2-Aminopurine Derivatives As CDK2 Inhibitors for Triple-Negative Breast Cancer

Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer.

Discovery of a Potent, selective and orally bioavailable CDK9 degrader for targeting transcription regulation in Triple-Negative breast cancer

Design, synthesis and biological assessment of novel CDK4 inhibitor with potent anticancer activity

Discovery of Novel PARP/PI3K Dual Inhibitors with High Efficiency Against BRCA-proficient Triple Negative Breast Cancer.

Design, Synthesis and Structure-Activity Relationship Studies of a Focused Library of Pyrimidine Moiety with Anti-Proliferative and Anti-Metastasis Activities in Triple Negative Breast Cancer.

Rational design, synthesis and biological evaluation of dual PARP-1/2 and TNKS1/2 inhibitors for cancer therapy.

Design, Synthesis, and Antitumor Activity of Benzimidazole Derivatives As CDK4/6 Inhibitors

Selective and Novel Cyclin-Dependent Kinases 4 Inhibitor: Synthesis and Biological Evaluation

Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer

Design, synthesis and biological evaluation of novel 1,3,4,9-tetrahydropyrano[3,4-b]indoles as potential treatment of triple negative breast cancer by suppressing PI3K/AKT/mTOR pathway